Evaluation of Belantamab Monotherapy and Combination Regimens in Patients with Multiple Myeloma: Safety and Clinical Activity Assessment

The primary objective of this study is to evaluate the **safety** and clinical activity of belantamab in the treatment of **multiple myeloma**. This investigation is crucial as it aims to determine the therapeutic potential and safety profile of belantamab, both as a monotherapy and in combination with other treatments, for patients with this hematologic malignancy. Understanding the safety and efficacy of belantamab could significantly impact treatment strategies and improve patient outcomes in multiple myeloma.

The clinical trial involves a total of **36 participants** diagnosed with **multiple myeloma**. The study population includes both male and female subjects, encompassing an age range that includes adults and older adults. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The selection process aimed to ensure a representative sample of individuals affected by the condition under investigation.

The clinical trial is designed to evaluate the **safety** and clinical activity of belantamab in the treatment of **multiple myeloma**. This study will be conducted as a randomized, double-blind, controlled trial, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias. The trial is set to commence recruitment on December 15, 2023, and is expected to conclude by June 28, 2027, providing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This visit is crucial for determining participant suitability for the trial. Following successful inclusion, participants will attend regular follow-up visits, which are scheduled to monitor the treatment's effects and any adverse reactions. These visits will include assessments such as physical examinations, laboratory tests, and questionnaires to gather data on the treatment's efficacy and safety. The end-of-study visit will mark the conclusion of the participant's involvement, where final evaluations will be conducted to assess the overall outcomes of the treatment.

The expected length of participant involvement will vary depending on individual response to the treatment and any unforeseen circumstances. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed necessary by the study investigators. Participants' health and safety are prioritized throughout the trial, with continuous monitoring to ensure any issues are promptly addressed.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial's efficacy assessment details are not explicitly provided in the source data. As such, specific parameters or endpoints, methods, and schedules for measuring, collecting, and analyzing efficacy are not available. The trial is categorized under phase 7, with an estimated recruitment start date of December 15, 2023, and an estimated end date of June 28, 2027. Further information regarding efficacy assessment tools or instruments is not included in the provided data.